Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$43.7 million.

  • CG Oncology's Income from Continuing Operations fell 11422.34% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 10798.61%. This contributed to the annual value of -$88.0 million for FY2024, which is 8136.16% down from last year.
  • Per CG Oncology's latest filing, its Income from Continuing Operations stood at -$43.7 million for Q3 2025, which was down 11422.34% from -$41.4 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Income from Continuing Operations peaked at -$8.7 million during Q1 2023, and registered a low of -$43.7 million during Q3 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$18.9 million (2024), whereas its average is -$23.3 million.
  • As far as peak fluctuations go, CG Oncology's Income from Continuing Operations tumbled by 6365.21% in 2024, and later plummeted by 11904.81% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's Income from Continuing Operations stood at -$16.6 million in 2023, then tumbled by 92.16% to -$31.8 million in 2024, then tumbled by 37.43% to -$43.7 million in 2025.
  • Its Income from Continuing Operations was -$43.7 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$34.5 million in Q1 2025.